-+ 0.00%
-+ 0.00%
-+ 0.00%

Scotts Miracle Gro (SMG) Stock May Be 35% Undervalued Despite Acquisition News

Simply Wall St·09/04/2026 01:28:21
语音播报

Scotts Miracle-Gro stock is coming off a difficult stretch, with shareholders facing a decline of about 53% over the past five years. Current valuation checks send a mixed message, as the intrinsic value estimate points to upside while traditional market multiples look roughly in line with peers.

  • The share price decline of about 53% over five years highlights how heavily longer term holders have already absorbed weaker performance and sentiment.
  • Recent news around the planned Black Kow acquisition may support expectations for future cash flow, while ongoing legal investigations and past inventory issues add uncertainty to how much value ultimately reaches shareholders.
  • With a value score of 4 out of 6, Scotts Miracle-Gro presents a mixed picture rather than a clear bargain or a clearly expensive stock on the broader checks.

The key question now is whether the current discount to the intrinsic value estimate fairly reflects the risks around Scotts Miracle-Gro, or if the stock price already captures most of that uncertainty.

Scan beyond Scotts Miracle-Gro and pressure-tested turnarounds by reviewing 53 high quality undervalued stocks with balance sheets and cash flows that have already survived tougher conditions.

Does Scotts Miracle-Gro Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here is based on projected free cash flows to equity and a terminal value for Scotts Miracle-Gro. Latest twelve month free cash flow sits at about $280 million, and the model assumes these cash flows grow moderately from this base rather than swinging sharply higher or lower. On those inputs, the DCF points to an intrinsic value around $91 per share, which is above the current market price and implies the stock screens about 34.8% undervalued.

The ongoing investigation into past financial disclosures helps explain why the price may still sit below that intrinsic estimate, since some investors could be marking down Scotts Miracle-Gro for governance and execution risk. Even so, the cash flow profile used in the model is relatively measured, which means the gap between price and DCF value is not driven by especially aggressive assumptions.

On this DCF view, Scotts Miracle-Gro stock looks undervalued relative to what its projected cash flows would support.

Our Discounted Cash Flow (DCF) analysis suggests Scotts Miracle-Gro is undervalued by 34.8%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

SMG Discounted Cash Flow as at Sep 2026
SMG Discounted Cash Flow as at Sep 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Scotts Miracle-Gro.

Is Scotts Miracle-Gro Fairly Priced on Earnings?

P/E is a useful cross check for Scotts Miracle-Gro because it links the stock price to the earnings that ultimately fund shareholder returns. Scotts Miracle-Gro currently trades on a P/E of about 22.3x, compared with a peer average of 19.5x and a broader chemicals industry average of 23.5x. That puts the stock at a modest premium to direct peers but a small discount to the wider industry.

The fair P/E ratio from the broader checks is about 20.5x, which is only slightly below the current level and indicates the market is pricing the stock close to what its risk profile and earnings power would justify. The gap is not large enough to signal a strong bargain or a clear stretch on this metric, particularly given the mixed sentiment associated with investigations and recent operational issues.

On the P/E multiple, Scotts Miracle-Gro appears to be priced roughly in line with what the earnings profile would support.

NYSE:SMG P/E Ratio as at Sep 2026
NYSE:SMG P/E Ratio as at Sep 2026

See what the numbers say about this price — find out in our valuation breakdown.

The Scotts Miracle-Gro Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this valuation puzzle for Scotts Miracle-Gro leaves off. They spell out what kind of growth, margins and earnings path would need to hold for Scotts Miracle-Gro's stock to be worth materially more or materially less than today's price, and each one frames fair value as a thesis about the business that you can revisit over time rather than a one off snapshot. These are available on Simply Wall St's Community page.

Community narratives on Scotts Miracle-Gro are split, with one camp treating current pricing as an opportunity and another calling out valuation risk.

Bull case: 26% undervalued

"S&P Global Ratings upgraded Scotts Miracle-Gro to BB from B+, citing its view of improved operating performance and credit metrics tied to higher-margin branded U.S. consumer products, supply chain savings, and sell-through trends, per S&P…"

Read the full Bull Case to see why Scotts Miracle-Gro could be undervalued

Bear case: 36% overvalued

"SMG’s current valuation reflects lingering skepticism: concerns over cannabis demand, consumer spending softness, and execution risk…"

Read the full Bear Case to see why Scotts Miracle-Gro could be overvalued

Do you think there's more to the story for Scotts Miracle-Gro? Head over to our Community to see what others are saying!

The Bottom Line

For Scotts Miracle-Gro, the Discounted Cash Flow (DCF) work suggests intrinsic value that is meaningfully above the current share price, while the P/E comparison says the stock is priced close to its peer group. That mix aligns with a middle of the road value score, which points to some potential upside but not a one sided setup. The real swing factor from here is whether cash flows and governance confidence hold up well enough for the market to close part of that DCF discount instead of keeping it as a penalty for legal and execution risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.